

# Siddharth Singh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3660130/publications.pdf>

Version: 2024-02-01

304  
papers

18,477  
citations

11608

70  
h-index

16127

124  
g-index

323  
all docs

323  
docs citations

323  
times ranked

18638  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 173-181.e5.	2.4	4
2	A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 555-562.	0.9	3
3	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
4	Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e750-e760.	2.4	6
5	Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 646-660.	1.1	5
6	Comparative Risk of Serious Infections With Tumor Necrosis Factor $\pm$ Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e74-e88.	2.4	18
7	Magnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e31-e50.	2.4	18
8	Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 364-372.	0.9	28
9	Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor $\pm$ Antagonists in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2510-2516.	1.1	3
10	Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2039-2048.	1.1	5
11	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 224-243.	0.6	9
12	Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2451-2461.	1.1	12
13	Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 398-413.	0.6	11
14	Association between pancreatic intraductal papillary mucinous neoplasms and extrapancreatic malignancies: A systematic review with meta-analysis. <i>European Journal of Surgical Oncology</i> , 2022, 48, 632-639.	0.5	3
15	Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2728-2740.e1.	2.4	15
16	Post-endoscopy Esophageal Neoplasia in Barrett's Esophagus: Consensus Statements From an International Expert Panel. <i>Gastroenterology</i> , 2022, 162, 366-372.	0.6	12
17	Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 447-454.e1.	2.4	4
18	Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2022, 117, 78-97.	0.2	22

#	ARTICLE	IF	CITATIONS
19	Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 717-736.	0.6	9
20	No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3115-3123.	1.1	2
21	Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1477-1484.	0.9	23
22	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
23	High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1289-1292.	0.9	2
24	Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1614-1617.	0.9	1
25	Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00484.	1.3	8
26	Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 894-907.	1.9	32
27	Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases. <i>BioDrugs</i> , 2022, 36, 197-203.	2.2	10
28	Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1475-1492.	0.6	20
29	Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030). <i>Gastroenterology</i> , 2022, 162, 1098-1110.e2.	0.6	5
30	Impact of Comorbid Psychiatric Disorders on Healthcare Utilization in Patients with Inflammatory Bowel Disease: A Nationally Representative Cohort Study. <i>Digestive Diseases and Sciences</i> , 2022, , .	1.1	3
31	Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2022, 163, 937-949.e2.	0.6	23
32	Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice. <i>Current Opinion in Gastroenterology</i> , 2022, 38, 337-346.	1.0	5
33	National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1068-1078.	0.9	12
34	Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2031-2045.e11.	2.4	121
35	Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2564-2569.	1.1	10
36	Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2054-2063.e14.	2.4	52

#	ARTICLE	IF	CITATIONS
37	Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1026-1034.	0.9	3
38	Comparative efficacy of first-line therapeutic interventions for achalasia: a systematic review and network meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 4305-4314.	1.3	20
39	Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1626-1633.	0.9	22
40	Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2021, 73, 68-78.	3.6	61
41	Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 511-518.e6.	2.4	28
42	Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1209-1217.e2.	2.4	12
43	Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 639-646.	0.9	5
44	Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1377-1386.e5.	2.4	17
45	Systematic Review of Prevalence, Risk Factors, and Risk for Metachronous Advanced Neoplasia in Patients With Young-Onset Colorectal Adenoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 680-689.e12.	2.4	20
46	Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 603-616.	0.9	25
47	Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 567-574.	0.6	14
48	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 784-793.	1.9	18
49	Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1513-1524.	0.9	1
50	Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2060-2067.	0.2	19
51	Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 1469-1472.	0.6	4
52	Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 206-207.	1.9	0
53	Providing the Best Care for Patients With Crohn's Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, 2557-2562.	0.6	3
54	Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. <i>Hepatology</i> , 2021, 74, 1509-1522.	3.6	9

#	ARTICLE	IF	CITATIONS
55	Expanding targeted immune modulators in ulcerative colitis. <i>Lancet</i> , 2021, 397, 2313-2315.	6.3	3
56	AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, 2512-2556.e9.	0.6	44
57	AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, 2496-2508.	0.6	139
58	Spotlight: Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, 2511.	0.6	10
59	A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	0
60	Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00380.	1.3	8
61	Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. <i>Gastroenterology</i> , 2021, 161, 107-115.e3.	0.6	17
62	Systematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 546-559.	1.9	6
63	Addition of Financial Incentives to Mailed Outreach for Promoting Colorectal Cancer Screening. <i>JAMA Network Open</i> , 2021, 4, e2122581.	2.8	12
64	Population-based Trends in Healthcare Utilization and National Healthcare Spending on Pancreatitis in North America. <i>Gastroenterology</i> , 2021, 161, 1698-1701.e5.	0.6	3
65	Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 880-889.	1.9	51
66	AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update. <i>Gastroenterology</i> , 2021, 161, 1011-1029.e11.	0.6	29
67	Systematic review with meta-analysis: the prevalence of post-colonoscopy colorectal cancers using the World Endoscopy Organization nomenclature. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1232-1242.	1.9	11
68	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2221.	2.4	0
69	Early-Age Onset Colorectal Neoplasia in Average-Risk Individuals Undergoing Screening Colonoscopy: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2021, 161, 1145-1155.e12.	0.6	31
70	Cost-Related Nonadherence to Medications Among US Adults With Chronic Liver Diseases. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2639-2650.	1.4	13
71	Gender Disparities in Food Security, Dietary Intake, and Nutritional Health in the United States. <i>American Journal of Gastroenterology</i> , 2021, 116, 584-592.	0.2	16
72	Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1277-1284.	0.9	7

#	ARTICLE	IF	CITATIONS
73	Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1215-1223.	0.9	13
74	Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 374-382.	1.9	54
75	Urban-Rural Disparities and Temporal Trends in Peptic Ulcer Disease Epidemiology, Treatment, and Outcomes in the United States. <i>American Journal of Gastroenterology</i> , 2021, 116, 296-305.	0.2	7
76	Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1002-1014.	3.7	114
77	Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2459-2464.	0.2	3
78	Editorial: risk of pneumonia in IBD—reading between the lines!. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1490-1491.	1.9	0
79	Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 957-958.	1.9	0
80	Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2020, 72, 561-576.	1.5	96
81	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	2.4	22
82	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 14-23.	2.4	108
83	Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 69-81.e3.	2.4	137
84	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-to-Severe Ulcerative Colitis and Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 515-523.	0.9	14
85	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65
86	Positioning Therapies in the Management of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1268-1279.	2.4	33
87	Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients With Solid Tumors Before Initiating Chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1600-1608.e4.	2.4	4
88	Management of Inflammatory Bowel Diseases in Special Populations: Obese, Old, or Obstetric. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1367-1380.	2.4	32
89	Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1939-1948.e7.	2.4	22
90	First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2179-2191.e6.	2.4	222



#	ARTICLE	IF	CITATIONS
91	Comparative Efficacy and Speed of Onset of Action of Infliximab vs Colimumab in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 424-431.e7.	2.4	15
92	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	1.9	26
93	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	1.9	30
94	P281 A serum biomarker panel can accurately identify the presence of mucosal ulcers in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S292-S293.	0.6	1
95	P302 Diagnostic accuracy of a serum-based biomarker panel for endoscopic activity in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S304-S304.	0.6	2
96	External Validation of the Oakland Score to Assess Safe Hospital Discharge Among Adult Patients With Acute Lower Gastrointestinal Bleeding in the US. <i>JAMA Network Open</i> , 2020, 3, e209630.	2.8	30
97	Editorial: pancreatic cancer risk in inflammatory bowel diseases "it's all relative. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 550-551.	1.9	2
98	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 669-681.	1.9	48
99	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097121.	1.4	7
100	Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 568-569.	1.9	0
101	Modified two-stage restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis of observational research. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1817-1830.	1.0	15
102	Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1008-1016.	1.9	27
103	Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. <i>Science Immunology</i> , 2020, 5, .	5.6	127
104	Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 159, 1262-1275.e7.	0.6	101
105	Effect of Lifestyle Factors on Outcomes in Patients With Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2020, 115, 832-840.	0.2	73
106	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.2	15
107	Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2437-2447.e6.	2.4	39
108	No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 481-491.	1.9	10

#	ARTICLE	IF	CITATIONS
109	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
110	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1649-1650.	2.4	0
111	Management of Inflammatory Bowel Diseases: Clinical Perspectives. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1249-1251.	2.4	1
112	AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 1450-1461.	0.6	355
113	AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 1465-1496.e17.	0.6	85
114	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	2.4	27
115	Risk of de novo inflammatory bowel disease among obese patients treated with bariatric surgery or weight loss medications. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1067-1075.	1.9	10
116	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1031-1038.	1.9	80
117	Prevention of paracetamol-induced circulatory dysfunction? A systematic review and network meta-analysis. <i>GastroHep</i> , 2020, 2, 92-101.	0.3	10
118	The Doctor Will Call You Now! Telemedicine in the Midst of a Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1688-1690.	2.4	18
119	Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. <i>Cancers</i> , 2020, 12, 874.	1.7	68
120	Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .	2.4	4
121	Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1574-1582.	1.9	5
122	Network Meta-Analyses in Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2020, 16, 315-318.	0.2	0
123	Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1615-1616.	1.9	1
124	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 630-637.e8.	2.4	254
125	Letter: preoperative anti-TNF therapy in Crohn's disease is not associated with increased complications following elective surgery. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 467-468.	1.9	1
126	Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 969-979.	1.3	52



#	ARTICLE	IF	CITATIONS
127	Letter: immunogenicity of anti-TNF in elderly IBD patients” authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 337-337.	1.9	0
128	Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 848-857.	1.9	40
129	Sa1769 “ Worldwide Incidence of Older-Onset Inflammatory Bowel Diseases in the 21ST Century: A Systematic Review of Population-Based Studies. <i>Gastroenterology</i> , 2019, 156, S-394-S-395.	0.6	4
130	Comparative accuracy of needle sizes and designs for EUS tissue sampling of solid pancreatic masses: a network meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 893-903.e7.	0.5	104
131	Mild-to-Moderate Ulcerative Colitis Guideline. <i>Gastroenterology</i> , 2019, 156, 768.	0.6	4
132	Editorial: combination immunosuppressive therapy to treat Crohn’s disease “ ready for all age groups? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1529-1529.	1.9	0
133	Network meta-analysis to inform positioning of biologics in patients with Crohn's disease: Promise and perils. <i>Bailliere’s Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101614.	1.0	6
134	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1201-1216.	0.6	25
135	Should We Divide Crohn’s Disease Into Ileum-Dominant and Isolated Colonic Diseases?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2634-2643.	2.4	85
136	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
137	US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1828-1837.	0.9	34
138	Early combined immunosuppression may be effective and safe in older patients with Crohn’s disease: post hoc analysis of REACT. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1188-1194.	1.9	24
139	Serum Concentrations of 7 $\beta$ -hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn’s Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2722-2730.e4.	2.4	26
140	Compared Abilities of Endoscopic Techniques to Increase Colon Adenoma Detection Rates: A Network Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2439-2454.e25.	2.4	64
141	Mailed Outreach Is Superior to Usual Care Alone for Colorectal Cancer Screening in the USA: A Systematic Review and Meta-analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2489-2496.	1.1	62
142	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
143	Response to Gupta and Hanauer. <i>American Journal of Gastroenterology</i> , 2019, 114, 535-536.	0.2	1
144	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 733-745.	0.2	42

#	ARTICLE	IF	CITATIONS
145	P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S354-S355.	0.6	0
146	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2137-2138.	2.4	2
147	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. <i>The Cochrane Library</i> , 2019, 11, CD001176.	1.5	15
148	Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2019, 114, 630-639.	0.2	53
149	Big Dreams With Big Data! Use of Clinical Informatics to Inform Biomarker Discovery. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00018.	1.3	7
150	AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 748-764.	0.6	194
151	AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, 769-808.e29.	0.6	88
152	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
153	Comparative outcomes in patients with ulcerâ€vs nonâ€ulcerâ€related acute upper gastrointestinal bleeding in the United Kingdom: a nationwide cohort of 4474 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 537-545.	1.9	9
154	Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1726-1728.	2.4	1
155	Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2019, 64, 382-390.	1.1	22
156	Development, Validation, and Comparative Assessment of an International Scoring System to Determine Risk of Upper Gastrointestinal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1121-1129.e2.	2.4	25
157	Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 709-718.e7.	2.4	34
158	Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 410-420.	0.9	28
159	Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1284-1292.e30.	2.4	51
160	Cryotherapy for persistent Barrettâ€™s esophagus after radiofrequency ablation: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 1396-1404.e1.	0.5	56
161	Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1316-1320.	0.9	18
162	High body mass index is associated with increased risk of treatment failure and surgery in biologica€reated patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1472-1479.	1.9	63

#	ARTICLE	IF	CITATIONS
163	Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 635-643.	0.6	147
164	Factors Associated With Progression of Barrett's Esophagus: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1046-1055.e8.	2.4	97
165	Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 596-604.	1.9	21
166	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1309-1319.e7.	0.6	56
167	The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 2068-2086.e5.	0.6	128
168	PROMises Made, PROMises To Be Kept: Patient-Reported Outcome Measures in Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 624-626.	2.4	9
169	Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 916-923.	0.9	27
170	Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1074-1081.	0.9	27
171	Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 27-38.e4.	2.4	147
172	Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 343-356.e3.	2.4	299
173	Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer-related Mortality. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 874-881.	0.6	164
174	Stent migration following endoscopic suture fixation of esophageal self-expandable metal stents: a systematic review and meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 675-681.	1.3	83
175	Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 514-522.	2.9	51
176	Population Health Management for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, 37-45.	0.6	58
177	Role of two-dimensional shear wave elastography in the assessment of chronic liver diseases. <i>Hepatology</i> , 2018, 67, 13-15.	3.6	9
178	Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 162-175.	1.9	187
179	Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1847-1850.e1.	2.4	21
180	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <i>American Journal of Gastroenterology</i> , 2018, 113, 1197-1205.	0.2	40

#	ARTICLE	IF	CITATIONS
181	Editorial: predicting recurrence of Crohn's disease after surgical resectionâ€”close to a crystal ball. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1156-1157.	1.9	3
182	Statin use and the risk of <i>Clostridium difficile</i> infection: a systematic review with meta-analysis. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 405-416.	1.1	7
183	Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2278-2284.	0.9	8
184	Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B. <i>Digestive and Liver Disease</i> , 2018, 50, 787-794.	0.4	22
185	Comparison of Endoscopic Dysplasia Detection Techniques in Patients With Ulcerative Colitis: A Systematic Review and Network Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2518-2526.	0.9	46
186	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicilate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 114-126.	1.9	12
187	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
188	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93
189	Evolution of Clinical Trials in Inflammatory Bowel Diseases. <i>Current Gastroenterology Reports</i> , 2018, 20, 41.	1.1	10
190	Sa1711 - Real World Comparative Risk of Serious Infection with Adalimumab, Vedolizumab, and Infliximab in Patients with Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2018, 154, S-365.	0.6	2
191	Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 742-753.	3.7	40
192	Reply. <i>Gastroenterology</i> , 2018, 154, 1203-1204.	0.6	0
193	Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. <i>American Journal of Gastroenterology</i> , 2018, 113, 883-889.	0.2	42
194	277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis. <i>Gastroenterology</i> , 2018, 154, S-68.	0.6	6
195	328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis. <i>Gastroenterology</i> , 2018, 154, S-82.	0.6	4
196	A Primer on Systematic Reviews and Meta-Analyses. <i>Seminars in Liver Disease</i> , 2018, 38, 103-111.	1.8	9
197	Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-to-severe Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 394-409.	1.9	146
198	Obesity and response to anti-tumor necrosis factor-Î± agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0195123.	1.1	196

#	ARTICLE	IF	CITATIONS
199	American Gastroenterological Association Institute Guidelines for the Diagnosis and Management of Acute Liver Failure. <i>Gastroenterology</i> , 2017, 152, 644-647.	0.6	90
200	Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 94-102.	3.7	107
201	Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2017, 152, 1042-1054.e1.	0.6	307
202	Integrated precision medicine: the role of electronic health records in delivering personalized treatment. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2017, 9, e1378.	6.6	45
203	Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1521-1530.e8.	2.4	124
204	Obesity is Associated with Inferior Response to Anti-TNF Therapy in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 152, S154.	0.6	4
205	American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. <i>Gastroenterology</i> , 2017, 152, 1544-1577.	0.6	208
206	American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis. <i>Gastroenterology</i> , 2017, 152, 1536-1543.	0.6	121
207	Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 110-121.	8.2	272
208	Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 665-674.e5.	2.4	124
209	Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1218-1225.e7.	2.4	34
210	How to Conduct and Interpret Systematic Reviews and Meta-Analyses. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e93.	1.3	40
211	Association of Gastric Acid Suppression With Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA Internal Medicine</i> , 2017, 177, 784.	2.6	120
212	Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 381-390.	1.9	34
213	Management of Crohn's Disease After Surgical Resection. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 563-575.	1.0	10
214	Reply. <i>Hepatology</i> , 2017, 66, 1359-1360.	3.6	0
215	Obesity is Associated with Worse Disease Activity in Patients with Inflammatory Bowel Diseases: An Internet Based Cohort Study. <i>Gastroenterology</i> , 2017, 152, S973-S974.	0.6	5
216	American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 153, 835-857.e6.	0.6	238

#	ARTICLE	IF	CITATIONS
217	American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 153, 827-834.	0.6	440
218	Pre-Morbid Obesity is Associated with Increased Risk of Developing Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2017, 152, S976-S977.	0.6	8
219	American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. <i>Gastroenterology</i> , 2017, 152, 271-275.	0.6	178
220	American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. <i>Gastroenterology</i> , 2017, 152, 277-295.e3.	0.6	110
221	Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 90-105.	0.4	39
222	Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2017, 4, S384-S384.	0.4	0
223	Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies. <i>Rheumatology</i> , 2016, 55, kev354.	0.9	67
224	Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: A pooled analysis. <i>Annals of Hepatology</i> , 2016, 15, 363-376.	0.6	37
225	Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy. <i>Liver Transplantation</i> , 2016, 22, 723-731.	1.3	59
226	Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1120-1129.e6.	2.4	61
227	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 284-306.	3.6	414
228	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 307-318.	3.6	62
229	Editorial: obesity in chronic liver diseases " increased infections. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 311-312.	1.9	1
230	Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 994-1003.	1.9	34
231	Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 775-784.	1.9	28
232	Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2016, 102, 49-59.	0.9	45
233	Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. <i>BMJ, The</i> , 2016, 355, i6188.	3.0	66
234	The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2016, 111, 1147-1155.	0.2	257



#	ARTICLE	IF	CITATIONS
235	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events. JAMA - Journal of the American Medical Association, 2016, 315, 2424.	3.8	614
236	Reply. Hepatology, 2016, 64, 694-694.	3.6	1
237	Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clinical Gastroenterology and Hepatology, 2016, 14, 65-70.	2.4	59
238	Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 150, 599-607.e7.	0.6	144
239	No Cancer Without a Colon? Think Again! Colorectal Cancer Risk After Colectomy for Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2016, 14, 807-808.	2.4	0
240	Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. Gastrointestinal Endoscopy, 2016, 83, 1090-1106.e3.	0.5	94
241	Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. European Radiology, 2016, 26, 1431-1440.	2.3	195
242	Premorbid Obesity and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 355-368.e2.	2.4	44
243	Obesity Is Associated with Worse Outcomes in Hospitalized Patients with Inflammatory Bowel Diseases: A Nationwide Analysis. American Journal of Gastroenterology, 2016, 111, S271.	0.2	10
244	Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World Journal of Gastroenterology, 2016, 22, 8999.	1.4	26
245	Letter: faecal diversion for severe perianal Crohn's disease - practical issues. Authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 42, 1237-1237.	1.9	0
246	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. The Cochrane Library, 2015, , CD001176.	1.5	99
247	Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology, 2015, 62, 1417-1432.	3.6	139
248	Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 783-792.	1.9	141
249	Effect of Medications on Risk of Cancer in Patients With Inflammatory Bowel Diseases. Mayo Clinic Proceedings, 2015, 90, 738-746.	1.4	44
250	Response. Gastrointestinal Endoscopy, 2015, 81, 484-485.	0.5	0
251	Familial Hypercholesterolemia—Epidemiology, Diagnosis, and Screening. Current Atherosclerosis Reports, 2015, 17, 482.	2.0	124
252	Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. Gastroenterology, 2015, 149, 958-970.e12.	0.6	144

#	ARTICLE	IF	CITATIONS
253	Spontaneous Bacterial Peritonitis (SBP) caused by Bacillus Cereus in an Alcoholic Patient: Case Report and Review of Literature. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, DD03-4.	0.8	1
254	Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 2241-2255.e4.	2.4	39
255	Crohn's disease: REACT to save the gut. Lancet, The, 2015, 386, 1800-1802.	6.3	4
256	Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis. Gastrointestinal Endoscopy, 2015, 82, 782-792.	0.5	48
257	Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 1907-1918.	2.4	60
258	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 212.	2.4	0
259	Comparative Efficacy of Pharmacologic Interventions in Preventing Relapse of Crohn's Disease After Surgery: A Systematic Review and Network Meta-analysis. Gastroenterology, 2015, 148, 64-76.e2.	0.6	97
260	Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 26-35.	8.2	82
261	Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology, 2015, 13, 643-654.e9.	2.4	1,199
262	Diagnostic Performance of Magnetic Resonance Elastography in Staging Liver Fibrosis: A Systematic Review and Meta-analysis of Individual Participant Data. Clinical Gastroenterology and Hepatology, 2015, 13, 440-451.e6.	2.4	427
263	Mistaken identity: normotensive scleroderma renal crisis. BMJ Case Reports, 2014, 2014, bcr2013202566-bcr2013202566.	0.2	1
264	Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 2135.	2.4	0
265	Letter: comparative efficacy of biological therapy in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 1432-1433.	1.9	4
266	Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis. Mayo Clinic Proceedings, 2014, 89, 1621-1635.	1.4	70
267	Physical Activity Is Associated with Reduced Risk of Gastric Cancer: A Systematic Review and Meta-analysis. Cancer Prevention Research, 2014, 7, 12-22.	0.7	39
268	Statins for prevention of hepatocellular cancer: One step closer?. Hepatology, 2014, 59, 724-726.	3.6	16
269	Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut, 2014, 63, 1229-1237.	6.1	242
270	Prevalence, Risk Factors, and Outcomes of Interval Colorectal Cancers: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2014, 109, 1375-1389.	0.2	222

#	ARTICLE	IF	CITATIONS
271	Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 457-478.	1.0	34
272	Effects of Simulation-Based Training in Gastrointestinal Endoscopy: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1611-1623.e4.	2.4	65
273	Accuracy of Spleen Stiffness Measurement in Detection of Esophageal Varices in Patients With Chronic Liver Disease: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 935-945.e4.	2.4	108
274	Identifying the presence of clinically significant hepatic involvement in hereditary haemorrhagic telangiectasia using a simple clinical scoring index. <i>Journal of Hepatology</i> , 2014, 61, 124-131.	1.8	32
275	Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 382-393.e1.	2.4	218
276	Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 210-218.	2.4	169
277	OC-060 Performance Characteristics Of Unsedated Ultrathin Video Endoscopy In The Assessment Of The Upper Gastrointestinal (gi) Tract: Systematic Review And Meta-analysis. <i>Gut</i> , 2014, 63, A29.2-A30.	6.1	1
278	Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy. <i>Hepatology</i> , 2014, 59, 735-736.	3.6	18
279	Neurologic Complications in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 864-872.	0.9	67
280	Primary Sclerosing Cholangitis: Diagnosis, Prognosis, and Management. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 898-907.	2.4	98
281	Statins Are Associated With Reduced Risk of Esophageal Cancer, Particularly in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 620-629.	2.4	159
282	Chronic Diarrhea After Autologous Stem Cell Transplantation for Peripheral T-cell Lymphoma. <i>Gastroenterology</i> , 2013, 145, e3-e5.	0.6	0
283	Management of Severe Steroid-Refractory Ulcerative Colitis: Cyclosporine or Infliximab?. <i>Gastroenterology</i> , 2013, 144, 1138-1140.	0.6	2
284	Bisphosphonates Are Associated With Reduced Risk of Colorectal Cancer: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 232-239.e1.	2.4	21
285	Predicting Clinical Outcomes With Elastography in Primary Biliary Cirrhosis: One Step Closer?. <i>Gastroenterology</i> , 2013, 144, 851-852.	0.6	1
286	Liver Stiffness Is Associated With Risk of Decompensation, Liver Cancer, and Death in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1573-1584.e2.	2.4	270
287	Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2013, 144, 323-332.	0.6	392
288	Central Adiposity Is Associated With Increased Risk of Esophageal Inflammation, Metaplasia, and Adenocarcinoma: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1399-1412.e7.	2.4	287

#	ARTICLE	IF	CITATIONS
289	Anti-Diabetic Medications and Risk of Pancreatic Cancer in Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2013, 108, 510-519.	0.2	106
290	Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2013, 108, 881-891.	0.2	265
291	Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2013, 24, 1721-1730.	0.6	131
292	Hepatocellular cancer risk in diabetes: Not all diabetics are the same. <i>Hepatology</i> , 2013, 58, 2207-2208.	3.6	1
293	Meta-analysis: serological markers and the risk of acute and chronic pouchitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 867-875.	1.9	42
294	Inflammatory Bowel Disease after Liver Transplantation for Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1417-1425.	0.2	72
295	Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2258-2268.	1.1	81
296	Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1631-1638.	0.9	68
297	Statin a day keeps cancer at bay. <i>World Journal of Clinical Oncology</i> , 2013, 4, 43.	0.9	17
298	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	0.6	12
299	Statins - the Holy Grail for cancer?. <i>Annals of Translational Medicine</i> , 2013, 1, 1.	0.7	5
300	Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know. <i>Mayo Clinic Proceedings</i> , 2012, 87, 779-790.	1.4	54
301	Medically diagnosed overweight and weight loss in a US national survey. <i>Preventive Medicine</i> , 2010, 51, 24-26.	1.6	13
302	Physician diagnosis of overweight status predicts attempted and successful weight loss in patients with cardiovascular disease and central obesity. <i>American Heart Journal</i> , 2010, 160, 934-942.	1.2	36
303	Interesting case presentation: neonatal hemochromatosis as a cause of ascites. <i>Journal of Perinatology</i> , 1990, 10, 214-6.	0.9	4
304	Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials. <i>Inflammatory Bowel Diseases</i> , 0, , .	0.9	0